Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children

Feder, Henry M.; Beran, Jiřı́; Hoecke, C. Van; Abraham, Betsy; Clercq, Norbert De; Buscarino, Charles; Parenti, Denis L.

doi:10.1016/s0022-3476(99)70055-7

Cited by 44 publications

(21 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results were refined by excluding 10 studies [16,17,[23][24][25][26][27][28][29][30] without detail data after more detailed analysis. The remaining 3 studies were included for meta-analysis [31][32][33]. The flow of study selection is shown in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis

Zhao

Bao

Liu

2017

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Lyme borreliosis, caused by Borrelia burgdorferi sensu stricto in the United States and by several Borrelia species in Europe and Asia, has a great impact on the health of the global population. There are human vaccines available, such as the outer surface protein A (OspA) vaccine, but still more evidence is needed to verify its function. We investigated the safety, immunogenicity, and efficacy of adjuvanted or non-adjuvanted vaccines containing protective epitopes from Borrelia species OspA serotypes in healthy adults. Methodology: Seven electronic databases were searched for clinical trials involving vaccine of OspA, with outcome data on safety, immunogenicity, and efficacy. The meta-analysis method was used to compare all vaccination strategies at the same time. Results: Three relevant studies were identified. All were randomized controlled trials (RCTs) or quasi-RCTs. Meta-analysis shows that, compared with low dose, high dose comes with a higher IgG titer with overall effect size of 6.39. For the 30 µg dose, the geometric mean titer was 6918.31, which is statistically significant when compared with 0. With respect to safety, only soreness showed a relatively high incidence of 40% (p < 0.05 when compared with 0, while the other side effects were no difference compared with 0). Conclusions: The OspA vaccine against Lyme disease is safe and its immunogenicity and efficacy have been verified. Instead of stagnating or giving up, further research on improving the vaccine is needed. On the foundation of preliminary studies, we can attempt to develop new vaccines for human use.

show abstract

Section: Resultsmentioning

confidence: 99%

Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis

Zhao

Bao

Liu

2017

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…Clinical trials in adults showed a 76% efficacy in preventing symptomatic Lyme disease after three doses (13). In children, vaccination efficacy has been shown to be close to 100% (14,15). A nonadjuvant, lipidated form of rOspA Lyme vaccine, ImuLyme [Pasteur Merieux Connaught USA, Swiftwater, PA (16)], was found to have 92% efficacy after three injections.…”

mentioning

confidence: 99%

An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope

Willett

Meyer

Brown

et al. 2004

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

The antigenic component of a common Lyme disease vaccine is recombinant outer surface protein A (rOspA) of Borrelia burgdorferi (Bb), the causative agent of Lyme disease. Coincidentally, patients with chronic, treatment-resistant Lyme arthritis develop an immune response against OspA, whereas those with acute Lyme disease usually do not. Treatment-resistant Lyme arthritis occurs in a subset of Lyme arthritis patients and is linked to HLA.DRB1*0401 (DR4) and related alleles. Recent work from our laboratory identified T cell crossreactivity between epitopes of OspA and lymphocyte function-associated antigen 1␣ L chain (LFA-1␣L) in these patients. We generated a form of rOspA, FTK-OspA, in which the LFA-1␣ L͞rOspA crossreactive T cell epitope was mutated to reduce the possible risk of autoimmunity in genetically susceptible individuals. FTK-OspA did not stimulate human or mouse DR4-restricted, WT-OspA-specific T cells, whereas it did stimulate antibody responses specific for WT-OspA that were similar to mice vaccinated WT-OspA. We show here that the protective efficacy of FTK-OspA is indistinguishable from that of WT-OspA in vaccination trials, as both C3H͞HeJ and BALB͞c FTKOspA-vaccinated mice were protected from Bb infection. These data demonstrate that this rOspA-derived vaccine lacking the predicted cross-reactive T cell epitope, but retaining the capacity to elicit antibodies against infection, is effective in generating protective immunity.

show abstract

“…The vaccine was safe and moderately efficacious (76% after 3 doses), as was a similar OspA vaccine that ultimately was not marketed (Sigal et al, 1998). Safety and immunogenicity was also demonstrated in 2-to 18-year-old children in the United States and Europe (Feder et al, 1999;Beran et al, 2000;Sikand et al, 2001).…”

Section: Preventing Lyme Disease By Immunizationmentioning

confidence: 94%

Prevention of Lyme Borreliosis

Sood

2011

Lyme Borreliosis in Europe and North America

View full text Add to dashboard Cite

Lyme borreliosis is an emerging infectious disease in both the Old and New worlds. The challenge for prevention of this tick-borne infection is greater than with other vector-borne infections because of the complex life cycle of its tick vectors. This can be exploited to decrease transmission to humans at multiple levels. (Hayes and Piesman, 2003). The opportunities for intervention can be divided into three main areas: prevention of tick exposure and of tick bites, prevention of infection after a tick bite, and immunization. Prevention of tick exposure includes the control of ticks and their reservoirs and hosts in nature, by multipronged efforts at landscape management, acaricide application, biological control of ticks, and control of host animals. Tick control and investigations aimed at decreasing the spirochetal burden in nature are discussed briefly in this chapter. For more information the reader is referred to comprehensive reviews, (Hayes

show abstract

Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children

Cited by 44 publications

References 11 publications

Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis

Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis

An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope

Prevention of Lyme Borreliosis

Contact Info

Product

Resources

About